NR3C2 and chronic kidney disease: The phase II program ARTS (MinerAlocorticoid Receptor antagonist Tolerability Study) was conducted in CKD patients with chronic heart failure and reduced ejection fraction (HFrEF), with spirololactone as a comparator (12).